Wuhan Hiteck Biopharmaceutical Co., Ltd. is a publicly listed biopharmaceutical company (Shenzhen Stock Exchange: 300683) dedicated to the discovery and development of innovative biologics and small-molecule therapeutics. Originating from the Medical School of Wuhan University, Hiteck has built an integrated R&D and manufacturing infrastructure supporting end-to-end drug development and translation. The company operates a state-of-the-art pharmaceutical industrial park with GMP-compliant facilities, enabling efficient progression from discovery to clinical and commercial supply.

The Company specializes in the development, manufacturing, and commercialization of bioengineered products and lyophilized injectables, and also conducts global import and export of its products and technologies. Currently, Hiteck holds 25 manufacturing licenses covering both biologics and chemical drugs. The company’s industrial park covers an area of 138,000 square meters, with a total building area of over 61,000 square meters, including more than 14,800 square meters of GMP-compliant manufacturing facilities that are fully equipped. Hiteck has established a comprehensive pharmaceutical quality management system and a well-structured quality management department, strictly implementing GMP requirements for drug manufacturing and total quality management to safeguard and continuously improve product quality. The Group employs over 1,000 professionals, including experienced scientists, engineers, and management personnel. The Company maintains close engagement with academic experts from leading universities and has established collaborative projects with renowned academicians. Guided by a strong core culture, the Company grows alongside its people and is committed to developing high-caliber management and technical talent grounded in integrity, gratitude, professionalism, and a spirit of progress.

Hiteck is recognized as a high-tech enterprise in Hubei Province and operates a nationally approved postdoctoral research workstation. It has established multiple innovation platforms focused on rare disease drug development and technology advancement, supported by five core technology platforms and pilot scale facilities that enable efficient industrialization and market translation of research outcomes.

The company focuses on the research, development, manufacturing, and commercialization of drugs for neurological disorders and oncology. Hiteck has successfully commercialized two National Class I innovative drugs:

Mouse Nerve Growth Factor Injection (NGF, brand name: 金路捷), indicated for neurological disorders.

Aponermin for Injection (brand name: 沙爱特), a first-in-class genetically engineered biologic with a novel mechanism of action, addressing significant unmet medical needs in oncology.

Guided by its mission of "Innovating for life", Hiteck is dedicated to advancing innovative therapies that address unmet medical needs and improve patient outcomes. Looking ahead, Hiteck will continue to expand its capabilities across biologics, small molecule drugs, and in vitro diagnostics, driven by sustained innovation and a patient centered approach, with the goal of building a leading innovative pharmaceutical group in China.